Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials

Autor: Byron J. Hoogwerf, Bertrand Cariou, Trevor J. Orchard, Henry N. Ginsberg, Edward J. Bastyr, Scott J. Jacober, Annette M. Chang, Junxiang Luo, Tibor Ivanyi, Lei Chen, Juliana M. Bue-Valleskey
Rok vydání: 2016
Předmět:
Adult
Blood Glucose
Male
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Insulin
Isophane
Adipose tissue
Insulin Glargine
030209 endocrinology & metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
Drug Administration Schedule
Polyethylene Glycols
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Internal medicine
Internal Medicine
medicine
Lipolysis
Humans
Hypoglycemic Agents
Triglycerides
Aged
Retrospective Studies
chemistry.chemical_classification
Glycated Hemoglobin
Type 1 diabetes
Insulin Lispro
Cholesterol
Insulin glargine
business.industry
Insulin
Fatty acid
Middle Aged
medicine.disease
Lipid Metabolism
Lipids
Diabetes Mellitus
Type 1
chemistry
Diabetes Mellitus
Type 2
Drug Therapy
Combination
Female
business
medicine.drug
Zdroj: Diabetes, obesitymetabolism. 18(11)
ISSN: 1463-1326
Popis: Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH) from phase III studies in type 1 diabetes (T1D), insulin-naive patients with type 2 diabetes (T2D), patients with T2D on basal insulin only and patients with T2D on basal-bolus therapy. BIL treatment had little effect on HDL cholesterol and LDL cholesterol in all patients. The effect of both BIL and glargine treatment on triglycerides (TG) depended on whether patients had been previously treated with insulin. When BIL replaced conventional insulin glargine or NPH treatments, increases in TG levels were observed. When BIL or comparator insulins were given for 26 weeks to insulin-naive patients with T2D, TG levels were unchanged from baseline with BIL but decreased with either glargine or NPH. The decreased peripheral action of BIL may reduce suppression of lipolysis in peripheral adipose tissue resulting in increased free fatty acid delivery to the liver and, hence, increased hepatic TG synthesis and secretion.
Databáze: OpenAIRE
Externí odkaz: